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Abstract
Introduction: The aim of this study was to evaluate in patients with resistant hypertension (RHTN) enrolled in the RESIST-POL study the relation-
ship between primary aldosteronism (PA) and obstructive sleep apnoea (OSA) and their effect on metabolic abnormalities and cardiac structure.
Material and methods: We included 204 patients (123 M, 81 F, mean age 48.4 yrs) with true RHTN, eGFR > 60 mL/min/1,73 m2 and no known 
diabetes. OSA was defined as an apnoea/hypopnoea index of 15/h or more. Metabolic syndrome components were assessed. On echocardiog-
raphy, left ventricular hypertrophy (LVH), concentric remodelling (RWT > 0.45), E’ velocity, E/E’ index and global strain (GLS) were evaluated.
Results: PA was diagnosed in 32 patients (15.7%). OSA occurred more frequently in patients with PA (59.4 v. 42.4%; p = 0.058). Patients 
were divided into four groups: PA+ OSA+ , PA+ OSA-, PA-OSA+ and PA–OSA–. Newly diagnosed diabetes, impaired glucose tolerance 
and increased fasting glucose were most frequent in the PA+ OSA+ group compared to other groups. The presence of OSA was associ-
ated with concentric remodelling, and the presence of PA was associated with higher left ventricular mass and higher frequency of left 
ventricular hypertrophy. In the PA+ OSA+ and PA+ OSA- groups, the most frequent geometry patterns were concentric hypertrophy 
(68.4%) and eccentric hypertrophy (54.5%) respectively. E’ velocity was lowest and E/E’ was highest in PA+ OSA+ compared to other 
groups. GLS was lower in patients with OSA compared to those without OSA.
Conclusions: Both metabolic abnormalities and target organ damage are more pronounced in patients with RHTN, PA and OSA. OSA 
and PA influence differently left ventricular geometry. (Endokrynol Pol 2013; 64 (5): 363–367)
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Streszczenie
Wstęp: Celem analizy była ocena związku pomiędzy pierwotnym hiperaldosteronizmem (PA) i obturacyjnym bezdechem sennym (OBS) 
w relacji do nasilenia zaburzeń metabolicznych i zmian struktury i funkcji lewej komory (LV) serca u chorych z prawdziwie opornym 
nadciśnieniem tętniczym (OPNT) włączonych do badania RESIST-POL.
Materiał i metody: Badaniem objęto 204 chorych (123 M, 81 K, średni wiek 48,4 lat) z OPNT, eGFR > 60 ml/min/1,73 m2 i bez rozpoznanej 
wcześniej cukrzycy. Istotny klinicznie OBS zdefiniowano, jako wskaźnik bezdechów i oddechów spłyconych (AHI) > 15/h. Oceniono 
składowe zespołu metabolicznego (MS). W badaniu echokardiograficznym oceniono: przerost LV (LVH), koncetnryczną przebudowę LV 
(RWT > 0,45), prędkość fali E’, wskaźnik E/E’ i globalne odkształcenie włókien podłużnych (GLS).
Wyniki: PA rozpoznano u 32 chorych (15,7%). OBS występował częściej u chorych z PA (59,4 v. 42,4%; p = 0,058). Chorych podzielono 
na cztery grupy: PA+ OBS+ , PA+ OBS-, PA-OBS+ and PA– OBS–. Świeżo wykryta cukrzyca, podwyższone stężenie glukozy na czczo 
i podwyższone stężenie glukozy po obciążeniu glukozą występowały najczęściej w grupie PA+ OBS +. OBS związany był z częstszym 
występowaniem koncentrycznej przebudowy LV, podczas gdy PA związany był z wyższą masą LV i częstszym występowaniem LVH. 
W grupach PA+ OBS+ I PA+ OBS – najczęstszymi typami geometrii LV były odpowiednio: przerost koncentryczny (68,4%) i przerost 
ekscentryczny (54,5%). Prędkość fali E’ była najniższa i wskaźnik E/E’ był najwyższy w grupie PA+ OBS +. GLS był niższy u chorych z 
OBS w porównaniu z chorymi bez OBS.
Wnioski: Zarówno zaburzenia metaboliczne jak i nasilenie zmian narządowych były najbardziej wyrażone u chorych z OPNT, u których 
współistniały PA i OBS. PA i OBS w różny sposób wpływały na geometrię LV. (Endokrynol Pol 2013; 64 (5): 363–367)
Słowa kluczowe: nadciśnienie tętnicze oporne, pierwotny hiperaldosteronizm, obturacyjny bezdech senny, zespół metaboliczny, przerost lewej komory
This study was supported by the Ministry of Science and Higher Education NN 402 190 335.
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Introduction
The prevalence of primary aldosteronism (PA) in the 
general hypertensive population remains an unre-
solved issue, but data from clinical practice indicates 
that resistant hypertension (RHTN) represents the 
condition with the highest probability of detecting PA 
[1–4]. Recent studies have indicated that in PA exposure 
to inappropriately elevated aldosterone might result in 
substantial cardiovascular and renal damage. One study 
that has reported prospective data upon treatment of 
PA found a higher cardiovascular and cerebrovascular 
risk for patients with PA at baseline [5]. 
The association of obstructive sleep apnoea (OSA) 
in hypertension is particularly marked among patients 
with RHTN, with studies reporting an OSA prevalence 
of 80% to 85% in these patients [6, 7]. As in other dis-
eases resulting from hormonal disturbances, the non-
dipping pattern of blood pressure during the night has 
been reported as a feature of patients with OSA [8]. 
Obstructive sleep apnoea is associated with increased 
cardiovascular morbidity and mortality. Recent data 
suggests that OSA is independently associated with 
the cardiovascular risk factors that comprise metabolic 
syndrome (MS) and its components [9, 10]. 
In the RESIST-POL study, we have recently shown 
that in the studied group of 204 patients with true RHTN, 
the prevalence of PA was 15.6%. PA also overlapped with 
MS and OSA [6]. Because the coexistence of PA and OSA 
in patients with resistant hypertension has been reported 
only by a few authors, we analysed the relationship be-
tween PA and OSA, metabolic abnormalities and cardiac 
structure in patients with true resistant hypertension 
enrolled in the RESIST-POL Study [6, 11, 12]. 
Material and methods
Consecutive patients aged 18–65 years with RHTN, 
confirmed on ambulatory blood pressure monitor-
ing, with preserved renal function (eGFR > 60 mL/ 
/min/1.73 m2) and with no history of known diabetes, 
referred to the Department of Hypertension, Institute 
of Cardiology, Warsaw Poland between 2009 and 2011, 
were included in the Resist-Pol study. The study was 
approved by the Ethics Committee of the National 
Institute of Cardiology, Warsaw and informed written 
consent was obtained from each patient [6]. 
The full protocol and main results of the RESIST-
POL study have been already published. In brief, 
patients with true RHTN were screened for coexisting 
conditions including metabolic abnormalities and OSA, 
secondary causes of HTN including PA as well as evalu-
ated for target organ damage. As the methodology of 
the RESIST-POL study has been described extensively 
previously, we summarise below the definitions used 
for the purpose of this analysis [6].
Abdominal obesity was defined as waist circumference 
> 102 cm and > 88 cm for women and men respectively [13]. 
Microalbuminuria was defined as 24h albumin excretion 
> 30 mg/24 h. Glucose and lipid metabolism abnormali-
ties were diagnosed on the basis of the 2007 European 
Society of Hypertension/European Society of Cardiology 
(ESH/ESC) guidelines — increased fasting plasma glucose 
FPG: ≥ 5.69 mmol/L; increased 2h post glucose (2hPG) 
loading glucose concentration: ≥ 7.8 mmol/L; diabetes was 
diagnosed if two measures of FPG were ≥ 7.0 mmol/L or 
2hPG > 11.0 mmol/L [13]. For diagnosis of metabolic 
syndrome, three out of five criteria had to be met: (1) 
BP ≥ 130/≥ 85 mm Hg — this criterion was met for all 
patients; (2) abdominal obesity — waist circumfer-
ence M > 102 cm, F > 88 cm; (3) HDL cholesterol 
M < 1.0 mmol/L, F < 1.2 mmol/L; (4) triglycerides 
> 1.7 mmol/L; and (5) FPG ≥ 5.6 mmol/L [13].
To screen for PA, the plasma aldosterone to renin 
ratio (ARR) was evaluated in all patients. To confirm the 
diagnosis of PA, further testing was performed in pa-
tients with increased ARR (> 30) and serum aldosterone 
concentration (> 15 ng/dL). The captopril challenge test 
was conducted to confirm the diagnosis of PA, which 
was made in patients showing failure of aldosterone to 
suppress more than 30%. Medication treatment was tai-
lored according to current guidelines [3, 14–16]. Contrast 
enhanced computer tomography was performed in each 
patient for the purpose of adrenal gland imaging [17]. 
All patients irrespective of the symptoms of OSA 
were evaluated by standard attended polysomnogra-
phy. The apnoea/hypopnoea index (AHI) indicating the 
number of apnoeic and hypopnoeic episodes per hour 
of sleep was calculated. For the purpose of this study, 
we defined OSA as AHI above 15/h indicating clinically 
significant moderate-to-severe OSA. 
The left ventricle mass (LVM) was calculated using 
the modified American Society of Echocardiography 
cube formula proposed by Devereux et al. and was 
indexed to body surface area to obtain the LVM index 
(LVMI) [18]. Left ventricular hypertrophy was defined as 
a LVMI ≥ 110 g/m2 for women and ≥ 125 g/m2 for men. 
Concentric geometry was present when relative wall 
thickness (RWT) > 0.45 [19]. Left ventricular systolic func-
tion was evaluated by left ventricular ejection fraction. Ad-
ditionally, using speckle tracking echocardiography, global 
longitudinal strain (GLS) was obtained. Left ventricular 
diastolic function was evaluated by mitral inflow velocities 
and TDI values and included: the ratio of the early (E) to 
late (A) diastolic peak transmitral flow velocity (E/A ratio), 
myocardial early-diastolic velocity (E’), and the E/E’ ratio.
Data analysis was carried out using statistical software 
PASW Statistics 18 (SPSS Inc., Chicago, IL, USA). The re-
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sults are presented as mean  ±  one standard deviation or 
median and interquartile range. The values of variables 
between groups were compared — continuous and dis-
crete variables: Mann-Whitney test or univariate ANOVA 
analysis with post-hoc t Dunnett test or T3 Dunnett test 
depending on Levene’s test of homogeneity of vari-
ances; categorical variables: chi2 test or Fisher’s exact test. 
P < 0.05 was considered statistically significant.
Results
Primary aldosteronism was diagnosed in 32 (15.7%) 
out of 204 patients (123 M, 81 F, mean age 48.4, range 
19–65 yrs) with true RHTN enrolled in the Resist-POL 
study. OSA occurred more frequently in patients with 
PA compared to patients without PA (59.4 v. 42.4%, 
p = 0.058). AHI was higher in patients with PA com-
pared to those without PA (27.1 ± 24.0 v. 20.7  ±  22.6; 
p = 0.024). Patients were divided into four groups based 
on the presence of PA and OSA: PA[+]OSA[+], PA[+] 
OSA[–], PA[–] OSA[+] and PA[–]OSA[–] (Table I). 
Abdominal obesity, newly diagnosed diabetes, in-
creased FPG and increased 2hPG concentrations were 
most frequent in the PA[+]OSA[+] group compared 
to the other groups; no differences in the frequency of 
other MS components were observed (Table I). The fre-
Table I. Clinical characteristics of patients in relation to the presence of obstructive sleep apnoea (OSA) and primary 
aldosteronism (PA)
Tabela I. Charakterystyka kliniczna chorych w zależności od współistnienia obturacyjnego bezdechu sennego (OSA) 
i pierwotnego hiperaldosteronizmu (PA)
OSA– PA– OSA+ PA– OSA– PA+ OSA+ PA+ p-value
Subjects n 99 73 13 19
Men/women 41/58 59/14 8/5 15/4  < 0.001
Age (years) 45.7 ± 10.8 50.8 ± 9.4 49.8 ± 13.7 52.5 ± 8.2 0.003
BMI [kg/m2] 28.7 ± 4.6 31.7 ± 4.5 28.3 ± 3.4 32.6 ± 3.3*  < 0.001
Number of antihypertensive drugs (n) 4 (3–5) 4 (4–5) 5 (3–5.5) 5 (4–6) 0.082
Abdominal obesity (%) 61.6 86.3 61.5 89.5 0.001
Increased fasting glucose (%) 44.4 60.3 61.5 73.7 0.045
Increased 2hPG (%) 15.4 40.9 63.6 66.71  < 0.001
Newly recognised diabetes (%) 5.1 19.2 15.4 42.11,*  < 0.001
Metabolic syndrome (%) 54.5 75.3 69.2 84.2 0.010
Sodium [mmol/L–1] 141 ± 3 143 ± 2 144 ± 2 143 ± 2  < 0.001
Potassium [mmol/L–1] 4.3 ± 0.4 4.4 ± 0.4 3.7 ± 0.5 3.9 ± 0.53  < 0.001
Fasting glucose [mmol/L–1] 5.6 ± 0.6 5.9 ± 1.0 5.7 ± 0.5 6.3 ± 1.1 0.007
Total cholesterol [mmol/L–1] 5.2 ± 1.1 5.1 ± 1.1 4.9 ± 0.9 4.3 ± 1.3 0.012
LDL cholesterol [mmol/L–1] 3.3 ± 1.0 3.3 ± 1.0 3.3 ± 0.8 2.6 ± 1.0 0.033
HDL cholesterol [mmol/L–1] 1.4 ± 0.4 1.2 ± 0.4 1.4 ± 0.4 1.3 ± 0.7 0.047
Triglyceride [mmol/L–1] 1.6 ± 1.1 1.8 ± 0.9 1.4 ± 0.7 1.3 ± 0.7 0.25
Creatinine level [µmol/L–1] 76 ± 18 83 ± 18 82 ± 23 82 ± 24 0.14
eGFR [mL/min/1.73 m–2] 90.5 ± 19.6 90.3 ± 20.2 90.0 ± 25.3 93.6 ± 26.0 0.93
Microalbuminuria (%) 21.3 20.6 30.0 61.12 0.003
Office SBP [mm Hg] 159 ± 23 160 ± 20 156 ± 13 170 ± 21 0.23
Office DBP [mm Hg] 95 ± 15 98 ± 14 92 ± 12 100 ± 11 0.33
Daytime SBP [mm Hg] 144 ± 20 143 ± 17 154 ± 17 151 ± 22 0.13
Daytime DBP [mm Hg] 89 ± 13 90 ± 12 92 ± 10 93 ± 12 0.53
Daytime heart rate (beats/min–1) 73 ± 12 72 ± 10 66 ± 8 67 ± 10 0.092
Night-time SBP [mm Hg] 129 ± 19 130 ± 15 145 ± 15 144 ± 232 0.001
Night-time DBP [mm Hg] 77 ± 13 79 ± 11 85 ± 12 84 ± 11 0.048
Night-time heart rate (beats/min–1) 66 ± 11 66 ± 11 63 ± 9 62 ± 11 0.51
Data is presented as mean  ±  SD or as median (interquartile range) unless otherwise stated; OSA — obstructive sleep apnoea; PA — primary aldosteronism;  
2hPG — 2h post glucose loading; BMI — body mass index; eGFR — estimated glomerular filtration rate; *p < 0.05; OBS+ PA+ v. OBS– PA+; 1p < 0.05; 2p < 0.01;  
3p < 0.001 OBS+ PA+ v. OBS+ PA–
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quency of microalbuminuria was highest in the PA[+]
OSA[+] group compared to the other groups (Table I).
The frequency of LVH was higher in the PA[+]OSA[+] 
group compared to the PA[–] OSA[+] group, and concen-
tric remodelling was more frequent in the PA[+]OSA[+] 
group compared to the PA[+]OSA[–] group (Table II). In 
the PA[+]OSA[+] and PA[–]OSA[+] groups, the most fre-
quent LV geometry pattern was concentric hypertrophy 
and in the PA[+]OSA[–] groups the most frequent was 
eccentric hypertrophy (Fig. 1). E’ velocity was lower and 
E/E’ was hFigher in the PA[+]OSA[+] group compared 
to all other groups. GLS was higher in patients with OSA 
compared to those without OSA (Table I). 
Discussion 
An interesting finding of our study is a high coexistence 
of clinically significant moderate-severe OSA in patients 
with PA. In patients with PA, the severity of OSA was 
more pronounced compared to those without PA. Also 
in patients with PA and OSA, glucose metabolism altera-
tions were most pronounced. 
In one study of 109 patients with resistant hyper-
tension, OSA was found in 84% of patients with PA, 
supporting the concept that in subjects with resistant 
hypertension, the severity of OSA is greater in those 
patients with hyperaldosteronism and correlates with 
the degree of aldosterone access [12]. In another study 
Table II. Echocardiographic parameters in relation to the presence of obstructive sleep apnoea (OSA) and primary aldosteronism (PA)
Tabela II. Parametry echokardiograficzne w zależności od współistnienia obturacyjnego bezdechu sennego (OSA) i pierwotnego 
hiperaldosteronizmu (PA)
OSA– PA– OSA+ PA– OSA– PA+ OSA+ PA+ p-value
Subjects (n) 99 73 13 19
LVEDd [mm] 51 ± 5 51 ± 5 55 ± 4 54 ± 6 0.018
LVESd [mm] 31 ± 4 31 ± 4 34 ± 5 31 ± 8 0.23
IVSDd [mm] 12 ± 2 13 ± 2 12 ± 2 14 ± 21,#  < 0.001
PWDd [mm] 12 ± 2 13 ± 1 12 ± 2 14 ± 21,#  < 0.001
LA area [cm-2] 18.8 ± 5.4 19.7 ± 5.2 21.3 ± 3.2 22.2 ± 4.6 0.073
EF (%) 70 ± 5 70 ± 5 67 ± 7 67 ± 10 0.095
GLS (%) –15.1 ± 3.8 –13.2 ± 3.5 –15.8 ± 2.4 –13.2 ± 3.6 0.006
E/A (ratio) 1.2 ± 0.4 1.0 ± 0.4 1.2 ± 0.4 1.0 ± 0.4 0.010
E’ (wave cm/s-1) 11.1 ± 3.4 9.3 ± 2.7 10.4 ± 3.6 7.0 ± 2.81,*  < 0.001
E/E’ (ratio) 7.7 ± 2.5 8.9 ± 2.9 8.1 ± 2.5 11.7 ± 4.02,#  < 0.001
RWT (ratio) 0.46 ± 0.07 0.50 ± 0.07 0.44 ± 0.06 0.54 ± 0.11#  < 0.001
RWT ≥ 0.45 (%) 49.5 75.0 27.3 84.2#  < 0.001
LVM [g] 234 ± 61 267 ± 62 273 ± 85 328 ± 882  < 0.001
LVMI [m/g-2] 121 ± 28 128 ± 28 138 ± 35 159 ± 393  < 0.001
LVH (%) 43.9 56.9 72.7 84.21 0.005
Data is presented as mean  ±  SD unless otherwise stated; OSA — obstructive sleep apnoea; PA — primary aldosteronism; LVEDd — end-diastolic left ventricular 
diameter; LVEDs — end-systolic left ventricular diameter; IVSDd — interventricular septum thickness; PWDd — posterior wall thickness; LA — left atrium; EF — 
ejection fraction; GLS — global longitudinal strain; E/A — ratio of the early to late diastolic peak transmitral flow velocity; E’ — tissue Doppler of early-diastolic 
ventricular filling velocity; E/E’ — ratio: ratio of early diastolic pulsed wave Doppler to early diastolic tissue Doppler; RWT — relative wall thickness; LVM — left 
ventricular mass; LVMI — left ventricular mass index, *p < 0.05; #p < 0.01; OBS+ PA+ v. OBS– PA+; 1p < 0.05; 2p < 0.01; 3p < 0.001 OBS+ PA+ v. OBS+ PA–
Figure 1. Frequency of left ventricular geometry patterns in 
relation to the presence of obstructive sleep apnea (OSA) and 
primary aldosteronism (PA)
Rycina 1. Częstość występowania typów geometrii lewej komory 
w zależności od współistnienia obturacyjnego bezdechu sennego 
(OBS) i pierwotnego hiperaldosteronizmu (PA)
367
Endokrynologia Polska 2013; 64 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
in 325 newly diagnosed hypertensive patients who 
were screened for the presence of OSA, 53 patients were 
confirmed to have OSA; out of these patients, 34% had 
PA. This supports a high prevalence of PA in patients 
with OSA [11]. 
The pathophysiologic mechanism underlying the 
co-occurrence of these conditions is at present un-
known and needs further elucidation. Inappropriate 
sodium and fluid retention characterise hyperaldo-
steronism, including patients with RHTN. Displacing 
fluid from the lower extremities to the neck results in 
upper airway narrowing, suggesting that upper airway 
oedema may contribute importantly to the pathogen-
esis of OSA in patients with PA and RHTN [1]. 
Previous studies showed that OSA or PA are associ-
ated with high prevalence of LVH [2, 5, 10, 20]. Our study 
showed that LVH and changes in diastolic function were 
more pronounced in patients with PA coexisting with 
OSA compared to patients with only one of these co-
morbidities. It is of interest that PA and OSA influence 
differently left ventricular geometry. The presence of 
OSA was associated with concentric remodelling, and the 
presence of PA was associated with higher left ventricular 
mass and higher frequency of left ventricular hypertrophy. 
Therefore patients with PA and OSA were characterised 
by frequent concentric hypertrophy, but patients with PA 
without OSA were characterised by frequent eccentric 
hypertrophy. Also Savard et al. compared patients with 
PA and essential hypertension and found greater LVMI 
and a higher prevalence of LVH in patients with PA [20]. 
Although it might be postulated that the inappropriate 
sodium and fluid retention characterising hyperaldo-
steronism might contribute to the development of LVH 
[21], other factors such as the co-existence of OSA may 
determine the LV geometry.
There were no differences between the analysed 
groups in terms of systolic function assessed by the ejec-
tion fraction. However, using a new method known as 
speckle tracking echocardiography we found subclinical 
systolic dysfunction in patients with OSA with or without 
PA. This finding confirms the significant impact of OSA 
on systolic function. It was supported by the results of 
Usui et al. that patients with OSA have worsened systolic 
function as assessed by the STE method [22]. 
It is also of interest that in our study we found that 
diastolic parameters were the most severely impaired 
in a group with coexisting OSA and PA. It may be 
secondary to LVH, cyclic ischaemia that is present in 
OSA, as well as to influence of aldosterone on increased 
myocardial fibrosis. 
In summary, the results indicate a high prevalence of 
OSA in patients with RHTN and PA. This may suggest 
that in patients with RHTN, PA may contribute to the 
increased severity of OSA, but it does not exclude the 
reverse, i.e. that OSA stimulates aldosterone release in 
these patients. This may also explain why patients with 
PA coexisting with OSA were characterised by more 
pronounced metabolic abnormalities and changes in 
cardiac structure than those without PA. It is also of in-
terest that PA and OSA influenced differently LV geom-
etry — PA was associated with more pronounced LVH, 
whereas OSA was associated with more pronounced 
concentric remodelling.
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